Protein

Improving cellulases production by Myceliophthora thermophila through disruption of protease genes

6 days ago   |   By Springer

Abstract
Objective
To identify main protease genes for the proteolytic degradation of cellulases in M. thermophila and generate a lower-proteases fungal host that can be used for further metabolic engineering to increase cellulase production and heterologous protein expression.
Results
Systematic transcriptomic analysis were conducted on the expression of proteases genes in M. thermophila genome and five highly expressed genes encoding extracellular proteases were selected for mutation analyses. A series of single- and multi-gene mutants of these five selected genes was constructed using...
Read more ...

 


Search by Tags

   Protein      Genome      Genomics      Metabolic engineering      Gene      Genes      Engineering  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Perceptive Unveils New $200M Fund to Invest in Early-Stage Biotechs

Perceptive Unveils New $200M Fund to Invest in Early-Stage Biotechs

Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at... Read more ...

Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule

Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule

Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug... Read more ...

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat... Read more ...

Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the... Read more ...

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other... Read more ...

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx

Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions... Read more ...

Artificial Pancreas Keeps Patients Healthier: A Perspective

Artificial Pancreas Keeps Patients Healthier: A Perspective

The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers... Read more ...

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3... Read more ...

AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...

Business Development Manager, Europe - Invetech - San Diego, CA

Selling a combination of consulting services and technical product solutions in biotech, cell and gene therapy markets. Global VP Commercial .From Fortive - Tue, 10 Dec 2019... Read more ...